Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 1256Neoplasms 1074Carcinoma, Non-Small-Cell Lung 874Prostatic Neoplasms 714Lung Neoplasms 596Colorectal Neoplasms 590Neoplasm Metastasis 452Multiple Myeloma 432Leukemia, Myeloid, Acute 423Pancreatic Neoplasms 370Ovarian Neoplasms 367Melanoma 324Carcinoma, Hepatocellular 299Squamous Cell Carcinoma of Head and Neck 276Brain Neoplasms 275Recurrence 273Stomach Neoplasms 245Head and Neck Neoplasms 241Glioblastoma 239Carcinoma, Renal Cell 227Lymphoma 226Triple Negative Breast Neoplasms 225Precursor Cell Lymphoblastic Leukemia-Lymphoma 222Hematologic Neoplasms 212Urinary Bladder Neoplasms 211Uterine Cervical Neoplasms 200Endometrial Neoplasms 199Sarcoma 195Glioma 194Lymphoma, Non-Hodgkin 188

Interventions

sparsentan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Proteinuria × 90 days × Clear all
NCT07224776 2026-05-18

Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria

Brigham and Women's Hospital

Phase 1 Not yet recruiting
20 enrolled

Neoplasms, Proteinuria

NCT07561957 2026-05-01

A Smart Phone Application to Improve Adoption of the 2024 Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease (CKD) Guidelines

St. James's Hospital, Ireland

Phase NA Recruiting
80 enrolled
Genitourinary

Kidney Diseases, Nephrotic Syndrome, Proteinuria, Tuberous Sclerosis, Renal Insufficiency, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡